Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and
Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors.
Phase:
Phase 1
Details
Lead Sponsor:
AnewPharma
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences